贝伐珠单抗胸腔内注射治疗肺癌相关恶性胸腔积液回顾性疗效分析  

Retrospective analysis of the efficacy of intrapleural injection of Bevacizumab in the treatment of lung cancer-related malignant pleural effusion

作　　者：张会珍 吴凤英[2] 李爱武[2] ZHANG Hui-zhen;WU Feng-ying;LI Ai-wu(Department of Respiratory, the First People's Hospital of Hefei City, Hefei 230001,China;Department of Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China)

机构地区：[1]安徽省合肥市第一人民医院呼吸内科,合肥230001 [2]上海市肺科医院肿瘤科,上海200433

出　　处：《肿瘤综合治疗电子杂志》2019年第2期11-14,共4页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金青年科学基金(81402381)

摘　　要：目的回顾性分析贝伐珠单抗胸腔内注射对肺癌相关恶性胸腔积液的疗效及安全性。方法选择2017年1月至2018年8月上海市肺科医院住院患者中明确诊断为肺癌伴有胸腔积液的患者,所有患者均给予胸腔穿刺置管,在常规抗肿瘤治疗的基础上给予贝伐珠单抗胸腔内注入。记录患者临床症状改善、胸腔积液控制情况及安全性。结果 34例患者中,男性20例,女性14例。贝伐珠单抗胸腔内注射控制癌性胸腔积液疗效明显,总有效率为82.4%,平均胸腔积液控制时间4.91个月,安全性良好,未见明显不良反应,有效改善患者生活质量。早期应用患者胸腔积液控制效果明显,EGFR/ALK驱动基因阳性患者与驱动基因阴性患者疗效上无统计学差异。结论贝伐珠单抗胸腔内注射治疗恶性胸腔积液有效率较高,不良反应少,能有效改善患者生活质量,早期应用效果明显,与患者基因突变状态无明显相关性。Objective The efficacy and safety of intrapleural injection of Bevacizumab in the treatment of lung cancer-related malignant pleural effusion were retrospectively analyzed. Method From January 2017 to August 2018, Shanghai Pulmonary Hospital inpatients in diagnosis for lung cancer patients with pleural effusion were selected, all patients were given thoracic puncture catheterization. On the basis of conventional anti-tumor treatment Beacizumab bead order were given, and the chest cavity injection.Record patients’ clinical symptoms improved, chest water control and security. Result Of the 34 patients, 20 were male, 14 were female, median age was 66 years. Intrapleural injection of Bevacizumab is effective in the control of malignant pleural effusion, with a total effective rate of 82.4%. The average duration of pleural effusion control is 4.91 months, with good safety and no obvious adverse reactions, effectively improving the quality of life of patients. Early application of patients with pleural fluid control effect is obvious,EGFR/ALK driver gene positive patients and negative patients with no significant difference in the efficacy of the driver gene.Conclusion Intrapleural injection of Bevacizumab for the treatment of malignant pleural effusion has a high effective rate and little adverse reaction, and can effectively improve the quality of life of patients. The early application of Bevacizumab has a significant effect, and there is no significant correlation with the mutation status of patients.

关 键 词：肺癌 贝伐珠单抗 恶性胸腔积液 

分 类 号：R734.2[医药卫生—肿瘤]